FDA To Review AstraZeneca Diabetes Drug For Heart Risks

Law360, New York (February 11, 2014, 7:54 PM EST) -- The U.S. Food and Drug Administration launched an investigation Tuesday into the safety of an AstraZeneca PLC diabetes drug after a recent study found that users of the medication were more likely to suffer heart failure than a control group.

The agency asked AstraZeneca to supply it with clinical trial data in order to examine a possible link between the drugmaker's saxagliptin and heart failure. Saxagliptin is marketed as Onglyza and Kombiglyze XR.

The request stems from a study that appeared in the New England Journal...
To view the full article, register now.